HEALTHCARE

An independent data monitoring committee has reported encouraging data from the Phase III LUNAR trial.

The FDA approved Hominis system is for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy.

The company's lead product EpiCheck is for the earlier detection of lung cancer.

There is serious concern that the return to school today after the Passover vacation will spark a rise in cases.

IBF focuses on investments in drug development and medical diagnostics companies in all stages.

The Israeli company remains on track and expects to submit an application to the FDA for its multi-source Nanox.ARC and the Nanox.CLOUD in 2021.

The company, MediCann, will invest €10 million into the InterCure Austrian subsidiary, which will be 51% owned by InterCure.

The Israeli company's ProSense treats early stage, low risk breast cancer.

"Globes" reveals the loopholes that have let thousands of Israelis living abroad visit for jabs, despite not being health fund members.

Veteran Israel medical device company Lumenis had its ups and downs, but with Tzipi Ozer-Armon in charge, its value has gone one-way.

Dr. Natalia Freund of Tel Aviv University explains how tuberculosis is not necessarily a disease of the past.

Public health experts see the infection rate rising despite the vaccinations and expect a difficult month ahead.

Picodya, based on Kibbutz Hatzerim of Netafim fame, has developed fast, reusable, and economical Lab-on-a-Chip technology.

Israel's impressive vaccine rollout will probably not be enough to beat the virus. So what next?

Cabinet advisor Prof. Eli Waxman of the Weizmann Institute insists that despite Israel's vaccine rollout, thousands more will die, if the lockdown is lifted too soon.